icon-folder.gif   Conference Reports for NATAP  
  EASL 45th Annual Meeting
April 14-18, 2010
Vienna, Austria
Back grey_arrow_rt.gif
Predictors of relapse among patients treated with standard- or induction-dose peginterferon alfa-2a (40KD) combined with standard- or higher-dose ribavirin in difficult-to-cure patients
  Reported by Jules Levin
EASL Apr 14-18 2010 Vienna Austria
K.R. Reddy,1 M.L. Shiffman,2 M. Rodriguez-Torres,3 I. Bakulin,4 H. Cheinquer,5 A. Horban,6 M. El-Kashab,7 L. Gheorghe,8 P. Buggisch,9 M. Rabbia,10 M. McKenna,11 S.A. Harrison,12 on behalf of the PROGRESS Study Investigators 1Hospital of the University of Pennsylvania, Philadelphia, PA, USA; 2Liver Institute of Virginia, Bon Secours Health System, Newport News, VA, USA; 3Fundacion de Investigacion De Diego Santurce, Santurce, PR, USA; 4State Postgraduate Medical Institute, Ministry of Defence of the Russian Federation, Moscow, Russia; 5Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil; 6Medical University Clinic of Infectious Diseases, Warsaw, Poland; 7Toronto Liver Centre, Toronto, ON, Canada; 8Fundeni Clinical Institute, Bucharest, Romania; 9University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 10Roche, Nutley, NJ, USA; 11Roche, Welwyn, UK; 12Brooke Army Medical Center, Houston, TX, This research was funded by Roche, Basel, Switzerland

Figure 1. Study design

ALT quotient = baseline alanine aminotransferase divided by the upper limit of normal for the local laboratory;
BMI = body mass index; NAS = non-alcoholic fatty liver disease activity score; SD = standard deviation
NAS comprises three histological features that are scored semi-quantitatively: steatosis (0-3), lobular inflammation (0-3) and hepatocellular ballooning (0-2). Steatosis in liver biopsy specimens was defined as the percentage of cells with fatty changes per high-powered field.
Figure 2. SVR and relapse in patients with an EOTR and who received ≥80% of the planned peginterferon alfa-2a (40KD) doses

Figure 3. MLR model of baseline factors associated with relapse

Figure 4. MLR model of baseline and on-treatment factors associated with relapse